Neurosense Therapeutics is trading 13.23% higher at $0.48 after rising from the August 28 close of $0.42, with no clear catalyst identified.
- No fresh company-specific announcement for August 31, 2026 was identified.
- Recent coverage concerns PrimeC’s completed Health Canada pre-NDS process and targeted December 2026 filing, but those announcements predate today’s move and do not establish causation.
- The broader market is modestly lower.